Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans

Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans

Fexuprazan is a new drug candidate in the potassium-competitive acid blocker (P-CAB) family. As proton pump inhibitors (PPIs), P-CABs inhibit gastric acid secretion and can be used to treat gastric acid-related disorders such as gastroesophageal reflux disease (GERD). Physiologically based pharmacok...

Full description

Bibliographic Details
Main Authors:	Yoo-Seong Jeong, Min-Soo Kim, Nora Lee, Areum Lee, Yoon-Jee Chae, Suk-Jae Chung, Kyeong-Ryoon Lee
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Pharmaceutics
Subjects:	DWP14012 fexuprazan human scaling physiologically based pharmacokinetic modeling potassium-competitive acid blocker
Online Access:	https://www.mdpi.com/1999-4923/13/6/813

Similar Items

Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans
by: Min-Soo Kim, et al.
Published: (2022-06-01)

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
by: JungJin Oh, et al.
Published: (2023-02-01)

A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State
by: Wonsuk Shin, et al.
Published: (2023-08-01)

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans
by: Min-Soo Kim, et al.
Published: (2023-03-01)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
by: Deok Yong Yoon, et al.
Published: (2021-09-01)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
by: Yoo-Kyung Song, et al.
Published: (2021-03-01)

In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes
by: Ju-Hyun Kim, et al.
Published: (2020-09-01)

Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics
by: Myongjae Lee, et al.
Published: (2022-05-01)

Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs
by: Beomseok Rhee, et al.
Published: (2022-06-01)

TC14012 enhances the anti-fibrosis effects of UC-MSCs on the liver by reducing collagen accumulation and ameliorating inflammation
by: Fan Ding, et al.
Published: (2024-02-01)

Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species
by: Yoo-Seong Jeong, et al.
Published: (2021-06-01)

Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers
by: Jong Kyu Park
Published: (2023-09-01)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine
by: Lixia He, et al.
Published: (2022-11-01)

Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study
by: Hye Kyung Jeon, et al.
Published: (2023-09-01)

Bioanalysis of alpelisib using liquid chromatography–tandem mass spectrometry and application to pharmacokinetic study
by: Seop Lee, et al.
Published: (2022-08-01)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
by: Shufang Liu, et al.
Published: (2023-12-01)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020-03-01)

Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms
by: Dongke Wang, et al.
Published: (2023-12-01)

TRPV1 Antagonist DWP05195 Induces ER Stress-Dependent Apoptosis through the ROS-p38-CHOP Pathway in Human Ovarian Cancer Cells
by: Yi-Yue Wang, et al.
Published: (2020-06-01)

Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics
by: Xinxin Yang, et al.
Published: (2023-12-01)

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model
by: Jinliang Chen, et al.
Published: (2022-11-01)

Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects
by: Xin Luo, et al.
Published: (2024-02-01)

A systematic review with meta‐analysis: Efficacy and safety of potassium‐competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis
by: Daniel M Simadibrata, et al.
Published: (2024-03-01)

In Vivo Toxicity and Pharmacokinetics of Polytetrafluoroethylene Microplastics in ICR Mice
by: Sijoon Lee, et al.
Published: (2022-05-01)

Seven‐day vonoprazan‐based triple therapy as first‐line Helicobacter pylori treatment in comparison with extended sequential therapy
by: Yu‐Tse Chiu, et al.
Published: (2023-02-01)

Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis
by: Yongqi Dong, et al.
Published: (2024-01-01)

Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation
by: Benny M. Amore, et al.
Published: (2023-05-01)

Physiologically Based Pharmacokinetic Modelling and Simulation to Predict the Plasma Concentration Profile of Doxorubicin
by: George A. Mystridis, et al.
Published: (2022-02-01)

Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations
by: Hafsa Hafsa, et al.
Published: (2022-11-01)

Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and <i>O</i>-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling
by: Hyeon-Cheol Jeong, et al.
Published: (2019-11-01)

The Impact of Low Cardiac Output on Propofol Pharmacokinetics across Age Groups—An Investigation Using Physiologically Based Pharmacokinetic Modelling
by: Karel Allegaert, et al.
Published: (2022-09-01)

History and Pharmacological Mechanism of Gastric Acid-suppressive Drugs
by: Dong Han Yeom, et al.
Published: (2023-09-01)

A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia
by: Samia Kalsoom, et al.
Published: (2024-02-01)

Vonoprazan - a new drug for inhibiting gastric acid secretion
by: Kacper Niewęgłowski, et al.
Published: (2022-08-01)

Acid Suppressive Drugs
by: Cheol Min Shin
Published: (2022-06-01)

Application of Pharmacokinetics Modelling to Predict Human Exposure of a Cationic Liposomal Subunit Antigen Vaccine System
by: Raj K. S. Badhan, et al.
Published: (2017-12-01)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
by: Lingling Ye, et al.
Published: (2022-08-01)

Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model
by: Yawen Yuan, et al.
Published: (2023-01-01)

Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling
by: Pieter-Jan De Sutter, et al.
Published: (2023-09-01)

A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
by: Erik Sjögren, et al.
Published: (2021-02-01)